Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin

Leukemia

Volumn 32, Issue 6, 2018, Pages 1349-1357

  Lavallée, Vincent Philippe ^a,b   Chagraoui, Jalila ^a   MacRae, Tara ^a   Marquis, Miriam ^b   Bonnefoy, Arnaud ^c,d   Krosl, Jana ^a   Lemieux, Sébastien ^a,b,c,d   Marinier, Anne ^a,b,c,d   Pabst, Caroline ^a   Rivard, Georges Étienne ^c,d   Hébert, Josée ^a,b,c   Sauvageau, Guy ^a,b,c  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; CD135 ANTIGEN; DEXAMETHASONE; LIPOCORTIN 2; PODOPLANIN; RETINOIC ACID; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SIX3; TRANSCRIPTION FACTORS IRX1; TRANSCRIPTION FACTORS UNCX; TRANSCRIPTOME; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; MEMBRANE PROTEIN; PDPN PROTEIN, HUMAN;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PLATELET COUNT; POINT MUTATION; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RNA SEQUENCE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOCYTOPENIA; TRANSCRIPTOMICS; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BLEEDING; COMPLICATION; GENETICS; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; ANIMALS; FEMALE; FLOW CYTOMETRY; HEMORRHAGE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MEMBRANE GLYCOPROTEINS; MICE; MIDDLE AGED; PLATELET AGGREGATION; THROMBOCYTOPENIA; TRANSCRIPTOME; TRETINOIN;

EID: 85044070038     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/s41375-018-0069-1     Document Type: Article

References (29)

1. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando S, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. New Engl J Med. 2013;369:111-21.
2. Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118:1248-54.
3. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128-34.
4. Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, et al. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 2010;116:5650-9.
5. Rovelli A, Biondi A, Rajnoldi CA, Conter V, Giudici G, Jankovic M, et al. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol. 1992;10:1413-8.
6. Mantha S, Tallman M, Soff GA. What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia?'. Curr Opin Hematol. 2016;23:121-6.
7. Kwaan HC, Cull EH. The coagulopathy in acute promyelocytic leukaemia - What have we learned in the past twenty years. Best Pract Res Clin Haematol. 2014;27:11-8.
8. Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N. All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood. 1994;84:3001-9.
9. Falanga A, Consonni R, Marchetti M, Locatelli G. Cancer procoagulant and tissue factor are differently modulated by all-transretinoic acid in acute promyelocytic leukemia cells. Blood. 1998;92:143-51.
10. Menell JS, Cesarman GM, Jacovina AT, McLaughlin M, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. New Engl J Med. 1999;340:994-1004.
11. Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu D, et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res. 2011;35:879-84.
12. Bennett B, Booth NA, Croll A. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol. 1989;71:511-7.
13. Dombret H, Scrobohaci M, Ghorra P, Zini J, Daniel M, Castaigne S, et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retnoic acid treatment. Leukemia. 1993;7:2-9.
14. Mantha S, Goldman DA, Devlin SM, Lee J-WW, Zannino D, Collins M, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017;129:1763-7.
15. Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, et al. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016; 30:1672-81.
16. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med. 2013;368:2059-74.
17. Lavallee V-P, Baccelli I, Krosl J, Wilhelm B, Barabe F, Gendron P, et al. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat Genet. 2015;47:1030-7.
18. Liu J-YY, Li N, Yang J, Li N, Qiu H, Ai D, et al. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci USA. 2010;107:17017-22.
19. Kroll MH, Biswas B, Budd JR, Durham P, Gorman RT, Gwise TE et al. Assessment of the diagnostic accuracy of laboratory tests using receiver operating characteristic curves; approved guidelinesecond edition. Clinical and Laboratory Standards Institute Document. 2011;31:1-45.
20. Beitinjaneh A, Jang S, Roukoz H, Majhail NS. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010;34:831-6.
21. Chang Y-W, Hsieh P-W, Chang Y-T, Lu M-H, Huang T-F, Chong K-Y, et al. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget. 2015;6:42733-48.
22. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes. 1999;48:426-9.
23. Schacht V, Ramirez MI, Hong Y-KK, Hirakawa S, Feng D, Harvey N, et al. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 2003;22:3546-56.
24. Uhrin P, Zaujec J, Breuss JM, Olcaydu D, Chrenek P, Stockinger H, et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood. 2010;115:3997-4005.
25. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282:25993-6001.
26. Riedl J, Preusser M, Mir Seyed Nazari P, Posch F, Panzer S, Marosi C, et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. 2017;129:1831-9.
27. Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res. 2008;28 (5B):2997-3006.
28. Rashidi A, Silverberg ML, Conkling PR, Fisher SI. Thrombosis in acute promyelocytic leukemia. Thromb Res. 2013; 131:281-9.
29. Mitrovic M, Suvajdzic N, Elezovic I, Bogdanovic A, Djordjevic V, Miljic P, et al. Thrombotic events in acute promyelocytic leukemia. Thromb Res. 2015;135:588-93.